These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12908510)

  • 1. Breast cancer vaccines: current research and future prospects.
    Cameron DA
    Expert Rev Vaccines; 2002 Jun; 1(1):29-34. PubMed ID: 12908510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination as a treatment for breast or ovarian cancer.
    Holmberg LA; Sandmaier B
    Expert Rev Vaccines; 2004 Jun; 3(3):269-77. PubMed ID: 15176943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine immunotherapy in breast cancer treatment: promising, but still early.
    Curigliano G; Spitaleri G; Dettori M; Locatelli M; Scarano E; Goldhirsch A
    Expert Rev Anticancer Ther; 2007 Sep; 7(9):1225-41. PubMed ID: 17892423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunizing against breast cancer: a new swing for an old sword.
    Curigliano G; Locatelli M; Fumagalli L; Goldhirsch A
    Breast; 2009 Oct; 18 Suppl 3():S51-4. PubMed ID: 19914543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anti-HER2 vaccines: The HER2 immunotargeting future?].
    Ladjemi MZ; Jacot W; Pèlegrin A; Navarro-Teulon I
    Pathol Biol (Paris); 2011 Jun; 59(3):173-82. PubMed ID: 19481373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy.
    Yuan S; Shi C; Liu L; Han W
    Expert Opin Biol Ther; 2010 Jul; 10(7):1037-48. PubMed ID: 20420512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MUC1 and breast cancer.
    Apostolopoulos V; Pietersz GA; McKenzie IF
    Curr Opin Mol Ther; 1999 Feb; 1(1):98-103. PubMed ID: 11249691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary breast cancer vaccine study shows promise.
    Bankhead C
    J Natl Cancer Inst; 2007 Jun; 99(11):836. PubMed ID: 17551143
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.
    Mittendorf EA; Storrer CE; Foley RJ; Harris K; Jama Y; Shriver CD; Ponniah S; Peoples GE
    Cancer; 2006 Jun; 106(11):2309-17. PubMed ID: 16596621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells.
    Rentzsch C; Kayser S; Stumm S; Watermann I; Walter S; Stevanoviç S; Wallwiener D; Gückel B
    Clin Cancer Res; 2003 Oct; 9(12):4376-86. PubMed ID: 14555509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cancer vaccines].
    Kyte JA
    Tidsskr Nor Laegeforen; 2006 Nov; 126(22):2969-73. PubMed ID: 17117197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines.
    Wiedermann U; Davis AB; Zielinski CC
    Breast Cancer Res Treat; 2013 Feb; 138(1):1-12. PubMed ID: 23340862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer vaccines: promise for the future or pipe dream?
    Mittendorf EA; Peoples GE; Singletary SE
    Cancer; 2007 Oct; 110(8):1677-86. PubMed ID: 17763371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunology and breast cancer: therapeutic cancer vaccines.
    Curigliano G; Rescigno M; Goldhirsch A
    Breast; 2007 Dec; 16 Suppl 2():S20-6. PubMed ID: 17706425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunologic approaches to breast cancer treatment.
    Sabel MS; Nehs MA
    Surg Oncol Clin N Am; 2005 Jan; 14(1):1-31, v. PubMed ID: 15541997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immune response to breast cancer, and the case for DC immunotherapy.
    Allan CP; Turtle CJ; Mainwaring PN; Pyke C; Hart DN
    Cytotherapy; 2004; 6(2):154-63. PubMed ID: 15203992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2).
    Acres B
    J BUON; 2007 Sep; 12 Suppl 1():S71-5. PubMed ID: 17935281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer.
    Park JW; Melisko ME; Esserman LJ; Jones LA; Wollan JB; Sims R
    J Clin Oncol; 2007 Aug; 25(24):3680-7. PubMed ID: 17704416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion.
    Czerniecki BJ; Koski GK; Koldovsky U; Xu S; Cohen PA; Mick R; Nisenbaum H; Pasha T; Xu M; Fox KR; Weinstein S; Orel SG; Vonderheide R; Coukos G; DeMichele A; Araujo L; Spitz FR; Rosen M; Levine BL; June C; Zhang PJ
    Cancer Res; 2007 Feb; 67(4):1842-52. PubMed ID: 17293384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase.
    Montgomery RB; Makary E; Schiffman K; Goodell V; Disis ML
    Cancer Res; 2005 Jan; 65(2):650-6. PubMed ID: 15695410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.